Abstract
Although interleukin-25 (IL-25) has been traditionally considered as a cytokine involved in T helper (Th) 2 cell-associated allergic diseases and host defence against helminthic parasites, recent studies have shown that IL-25 exerts negative effects on the initiation and progression of Th1/Th17-mediated pathologies. This later function of IL-25 is particularly evident at the gut level, where IL-25 could contribute to attenuate tissue-damaging immune responses. These new and exciting pre-clinical observations suggest that therapeutic interventions aimed at enhancing IL-25 activity could be useful in the management of patients with chronic gut inflammation.
Keywords: IL-25, IBD, Th1, Th17, TNF-, IFN-, NK cells, gut, gut immune, cytokines
Inflammation & Allergy - Drug Targets (Discontinued)
Title: Interleukin-25 Negatively Controls Pathogenic Responses in the Gut
Volume: 10 Issue: 3
Author(s): Eleonora Franze, Angelamaria Rizzo, Roberta Caruso, Francesco Pallone and Giovanni Monteleone
Affiliation:
Keywords: IL-25, IBD, Th1, Th17, TNF-, IFN-, NK cells, gut, gut immune, cytokines
Abstract: Although interleukin-25 (IL-25) has been traditionally considered as a cytokine involved in T helper (Th) 2 cell-associated allergic diseases and host defence against helminthic parasites, recent studies have shown that IL-25 exerts negative effects on the initiation and progression of Th1/Th17-mediated pathologies. This later function of IL-25 is particularly evident at the gut level, where IL-25 could contribute to attenuate tissue-damaging immune responses. These new and exciting pre-clinical observations suggest that therapeutic interventions aimed at enhancing IL-25 activity could be useful in the management of patients with chronic gut inflammation.
Export Options
About this article
Cite this article as:
Franze Eleonora, Rizzo Angelamaria, Caruso Roberta, Pallone Francesco and Monteleone Giovanni, Interleukin-25 Negatively Controls Pathogenic Responses in the Gut, Inflammation & Allergy - Drug Targets (Discontinued) 2011; 10 (3) . https://dx.doi.org/10.2174/187152811795564028
DOI https://dx.doi.org/10.2174/187152811795564028 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Idiosyncratic Drug Hepatotoxicity: Strategy for Prevention and Proposed Mechanism
Current Medicinal Chemistry Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Current Medicinal Chemistry PEGylated Liposomes Incorporated with Nonionic Surfactants as an Apomorphine Delivery System Targeting the Brain: In Vitro Release and In Vivo Real-time Imaging
Current Nanoscience An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Nucleic Acids Electrotransfer In Vivo: Mechanisms and Practical Aspects
Current Gene Therapy Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Current Pharmaceutical Design Influence of Length and Amino Acid Composition on Dimer Formation of Immunoglobulin based Chimera
Current Pharmaceutical Design Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology
Combinatorial Chemistry & High Throughput Screening Therapeutic Effects of Micronutrient Supplements on Sperm Parameters: Fact or Fiction?
Current Pharmaceutical Design Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Microfluidic Assembly of Lipid Nanoparticles for Delivery of Antisense Oligonucleotides
Current Pharmaceutical Biotechnology Genomic Instability and Cancer
Current Molecular Medicine Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers
Current Drug Delivery Meet Our Editorial Board Member:
Current Genomics